Probi, Symrise launch probiotic-based skincare ingredient, SymFerment
Probi, in collaboration with Symrise, created a new skincare ingredient, SymFerment, a moisturizing active ingredient based on a byproduct from Probi’s probiotic derived from the fermentation of Lactiplantibacillus (Lactobacillus).
Photo © iStockphoto.com/Osuleo
Probi (Lund, Sweden), in collaboration with Symrise, created a new skincare ingredient, SymFerment, a moisturizing active ingredient based on a byproduct from Probi’s probioticderived from the fermentation of Lactiplantibacillus (Lactobacillus).
“By using a by-product from our regular production, our waste is upcycled and processed into new products,” said Andy McShea, COO, Probi, in a press release. “Part of the amount of water we use in production can therefore be reused. This is not only good for our gross margins in production but for use of resources in terms of water consumption.”
“Consumers are increasingly asking for sustainable cosmetic products,” says Léa Schmidt, global product manager at Symrise. “That’s why sustainability always forms the heart of our product development efforts. Thanks to the partnership with Probi, we can use valuable by-products from the production of probiotics to create effective ingredients such as SymFerment.”
Symrise will present the ingredient at in-cosmetic Global trade fair in Paris in April 2022.
Kratom sees impressive sales growth despite its regulatory status and stigma
March 12th 2025Despite its controversy, kratom is a top-selling ingredient that consumers see value in. That said, brands need to work hard to demonstrate safety and quality of kratom products in the absence of legal regulatory status. Will kratom be able to overcome its stigma for even more growth and consumer acceptance?
DOJ asks Utah court to dismiss FTC lawsuit against Xlear Inc.
March 11th 2025On March 10, the DOJ and the defendant filed a stipulation to dismiss with prejudice the lawsuit in which each party agrees “to be responsible for its own costs and fees and agrees that no party shall be responsible to any other party for any fines, costs, fees, or penalties arising from this case.”
HHS announces efforts to eliminate independent conclusion of GRAS
Published: March 11th 2025 | Updated: March 11th 2025U.S. Department of Health and Human Services (HHS) Secretary, Robert F. Kennedy Jr., is directing the acting U.S. Food and Drug Administration’s (FDA) acting commissioner to explore rulemaking that would eliminate the independent conclusion of GRAS provision.
